JP2020516679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516679A5 JP2020516679A5 JP2020504290A JP2020504290A JP2020516679A5 JP 2020516679 A5 JP2020516679 A5 JP 2020516679A5 JP 2020504290 A JP2020504290 A JP 2020504290A JP 2020504290 A JP2020504290 A JP 2020504290A JP 2020516679 A5 JP2020516679 A5 JP 2020516679A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- cycloalkyl
- heteroaryl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 194
- 125000003118 aryl group Chemical group 0.000 claims description 128
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 120
- 229910052739 hydrogen Inorganic materials 0.000 claims description 120
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 108
- 125000001072 heteroaryl group Chemical group 0.000 claims description 108
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 102
- 229910052799 carbon Inorganic materials 0.000 claims description 77
- -1 pentafluorophenoxy, tetrafluorophenoxy Chemical group 0.000 claims description 72
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
- 150000001875 compounds Chemical class 0.000 claims description 49
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 48
- 125000005843 halogen group Chemical group 0.000 claims description 46
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 44
- 125000003545 alkoxy group Chemical group 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 38
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 38
- 125000000304 alkynyl group Chemical group 0.000 claims description 36
- 125000004429 atom Chemical group 0.000 claims description 36
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 34
- 125000002252 acyl group Chemical group 0.000 claims description 34
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 32
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 26
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 16
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 16
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 16
- 229910004013 NO 2 Inorganic materials 0.000 claims description 16
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 16
- 125000003435 aroyl group Chemical group 0.000 claims description 16
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 16
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 16
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 16
- 101150079125 DCN1 gene Proteins 0.000 claims description 13
- 102100026982 DCN1-like protein 1 Human genes 0.000 claims description 13
- 101100330861 Homo sapiens DCUN1D1 gene Proteins 0.000 claims description 13
- 125000002723 alicyclic group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 claims description 9
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- AZNMFVGFAFVVDA-UHFFFAOYSA-N 4-methyl-5-phenyl-1,3-oxazole Chemical compound N1=COC(C=2C=CC=CC=2)=C1C AZNMFVGFAFVVDA-UHFFFAOYSA-N 0.000 claims description 8
- DNHKSCAYDWTXHD-UHFFFAOYSA-N 4-methyl-5-phenyl-1,3-thiazole Chemical compound N1=CSC(C=2C=CC=CC=2)=C1C DNHKSCAYDWTXHD-UHFFFAOYSA-N 0.000 claims description 8
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 8
- 239000005977 Ethylene Substances 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000005549 heteroarylene group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000017788 Cydonia oblonga Nutrition 0.000 claims description 6
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000005282 allenyl group Chemical group 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 150000007857 hydrazones Chemical class 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 150000002923 oximes Chemical class 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 101000644669 Homo sapiens NEDD8-conjugating enzyme Ubc12 Proteins 0.000 claims description 2
- 206010067125 Liver injury Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 102100020710 NEDD8-conjugating enzyme Ubc12 Human genes 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 231100000753 hepatic injury Toxicity 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000000451 tissue damage Effects 0.000 claims description 2
- 231100000827 tissue damage Toxicity 0.000 claims description 2
- 208000037816 tissue injury Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 C*N(**)*1CC(C)N*(C)*C1 Chemical compound C*N(**)*1CC(C)N*(C)*C1 0.000 description 11
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ZZGOFEVGYOFEQO-UHFFFAOYSA-N CCC[N](C)(C)CC Chemical compound CCC[N](C)(C)CC ZZGOFEVGYOFEQO-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483640P | 2017-04-10 | 2017-04-10 | |
| US62/483,640 | 2017-04-10 | ||
| PCT/US2018/026789 WO2018191199A1 (en) | 2017-04-10 | 2018-04-10 | Covalent small molecule dcn1 inhibitors and therapeutic methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516679A JP2020516679A (ja) | 2020-06-11 |
| JP2020516679A5 true JP2020516679A5 (enExample) | 2021-04-15 |
| JP7086171B2 JP7086171B2 (ja) | 2022-06-17 |
Family
ID=62067873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504290A Active JP7086171B2 (ja) | 2017-04-10 | 2018-04-10 | 共有結合性小分子ｄｃｎ１阻害物質およびそれを使用する治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10500194B2 (enExample) |
| EP (1) | EP3609876B1 (enExample) |
| JP (1) | JP7086171B2 (enExample) |
| CN (1) | CN110740996B (enExample) |
| AU (1) | AU2018251687B2 (enExample) |
| CA (1) | CA3059256C (enExample) |
| ES (1) | ES2916449T3 (enExample) |
| WO (1) | WO2018191199A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| CA3119781A1 (en) * | 2018-11-20 | 2020-05-28 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| IL323757A (en) | 2019-03-15 | 2025-12-01 | Fulcrum Therapeutics Inc | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
| EP4259132A4 (en) * | 2020-12-10 | 2025-01-15 | Adgero Biopharmaceuticals Holdings, Inc. | METHODS OF TREATMENT OF METASTATIC SKIN CANCER |
| CN112830957B (zh) * | 2021-01-07 | 2022-07-22 | 江西师范大学 | 一种制备卡非佐米的方法 |
| WO2023059605A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023059582A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| IL316803A (en) | 2022-06-06 | 2025-01-01 | C4 Therapeutics Inc | Bicyclic glutarimide-modified cervalon-binding agents |
| CN116987062A (zh) * | 2023-08-03 | 2023-11-03 | 中国热带农业科学院分析测试中心 | 一种氨基酸键联槟榔碱衍生物的制备方法 |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| US12435087B2 (en) | 2023-11-03 | 2025-10-07 | Cellarity, Inc. | Modulators of DCN-1 and methods of use thereof |
| US12473285B2 (en) | 2023-11-03 | 2025-11-18 | Cellarity, Inc. | DCN-1 modulating compounds and methods of use thereof |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234264A (en) * | 1989-06-29 | 1993-05-26 | Warner Lambert Co | N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions |
| AU2016324483B2 (en) * | 2015-09-18 | 2021-07-29 | Memorial Sloan Kettering Cancer Center | Methods and compositions of inhibiting DCN1-UBC12 interaction |
-
2018
- 2018-04-10 JP JP2020504290A patent/JP7086171B2/ja active Active
- 2018-04-10 WO PCT/US2018/026789 patent/WO2018191199A1/en not_active Ceased
- 2018-04-10 EP EP18720910.1A patent/EP3609876B1/en active Active
- 2018-04-10 CN CN201880038225.2A patent/CN110740996B/zh active Active
- 2018-04-10 US US15/949,799 patent/US10500194B2/en active Active
- 2018-04-10 AU AU2018251687A patent/AU2018251687B2/en active Active
- 2018-04-10 CA CA3059256A patent/CA3059256C/en active Active
- 2018-04-10 ES ES18720910T patent/ES2916449T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2278454T3 (es) | Compuestos de imidazol sustituido que tienen actividad inhibitoria de citoquinas. | |
| JP2024543976A5 (enExample) | ||
| US20230116062A1 (en) | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis | |
| JP2020510015A5 (enExample) | ||
| JP2019525962A (ja) | ケモカイン受容体調節剤及びそれの使用 | |
| JP2021535174A5 (enExample) | ||
| JP2008508214A5 (enExample) | ||
| US10875866B2 (en) | Pyrrolo[1,2-B]pyridazine derivatives | |
| RU2012142550A (ru) | Производные пирролопиразина и их применение в качестве ингибиторов jak и syk | |
| JPH07500108A (ja) | 抗アレルギー、抗炎症および腫瘍壊死因子抑制活性を有するシクロペンタンおよびシクロペンテン誘導体 | |
| WO2018026812A1 (en) | Antiviral agents | |
| CN109790170B (zh) | Gaba(a)受体调节剂和控制哮喘中气道高反应性和炎症的方法 | |
| ES2396671T3 (es) | Derivados de la indolilmaleimida como inhibidores de la proteína quinasa | |
| JP6982716B2 (ja) | 複素環式化合物及びその使用 | |
| ATE410168T1 (de) | A1 adenosin-rezeptor-antagonisten | |
| JP2020502106A5 (enExample) | ||
| US9340539B2 (en) | Hepatitis C inhibitor compounds | |
| JP6933763B2 (ja) | 肺高血圧症の急性又は慢性処置のためのｍｉｆ阻害剤 | |
| CN103827100B (zh) | 用于降低血清尿酸的[1,2,4]噻二嗪1,1-二氧化物化合物 | |
| JP2005506324A5 (enExample) | ||
| EP1196169A1 (en) | Compounds having cytokine inhibitory activity | |
| HK1217299B (en) | Mif inhibitors for the acute or chronic treatment of pulmonary hypertension | |
| JP2001500122A (ja) | イミダゾール化合物、組成物および使用 |